ReviewBioMed research international2019
Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy.
Review in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.Molecular cancer therapeutics · 2026Review
- Icaritin inhibits breast cancer through activating MT1X to promote ferroptosis and synergizing with NF-κB pathway suppression.Frontiers in oncology · 2026Article
- Drug protection against radiation-induced neurological injury: mechanisms and developments.Archives of toxicology · 2025Review
- Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.Military Medical Research · 2024Review
- Advanced PROTAC and Quantitative Proteomics Strategy Reveals Bax Inhibitor-1 as a Critical Target of Icaritin in Burkitt Lymphoma.International journal of molecular sciences · 2024Article
- MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging and disease · 2024Review
- Hyaluronic acid-modified liposomes PotentiatedFrontiers in pharmacology · 2024Article
- Advancements in the Biotransformation and Biosynthesis of the Primary Active Flavonoids Derived fromMolecules (Basel, Switzerland) · 2023Review
- Anhydroicaritin suppresses tumor progression via the PI3K/AKT signaling pathway in hepatocellular carcinoma.Aging · 2023Article
- Multidisciplinary strategies to enhance therapeutic effects of flavonoids from Epimedii Folium: Integration of herbal medicine, enzyme engineering, and nanotechnology.Journal of pharmaceutical analysis · 2023Review
- Dietary Epimedium extract supplementation improves intestinal functions and alters gut microbiota in broilers.Journal of animal science and biotechnology · 2023Article
- Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology.Frontiers in pharmacology · 2023Article
- Article
- Polyphenols as Lung Cancer Chemopreventive Agents by Targeting microRNAs.Molecules (Basel, Switzerland) · 2022Review
- Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway.Experimental and therapeutic medicine · 2022Article
- Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation.Molecules (Basel, Switzerland) · 2022Review
- Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges.Frontiers in pharmacology · 2022Review
- Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- Huanglian Jiedu Decoction for treatment of multiple myeloma: A protocol for a systematic review and meta-analysis.Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematological malignancies are still incurable. Therefore, research for novel treatment options was continuing with the natural product as one source. Icaritin is a compound extracted from a traditional Chinese herb,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.